Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient

Journal of Clinical Microbiology

Volumn 36, Issue 10, 1998, Pages 2893-2899

  Kew, Olen M ^a   Sutter, Roland W ^b   Nottay, Baldev K ^a   Mcdonough, Michael J ^a   Prevots, D Rebecca ^b   Quick, Linda ^b   Pallansch, Mark A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; ORAL POLIOMYELITIS VACCINE; VIRUS RNA; VIRUS VACCINE;

ARTICLE; CASE REPORT; COMMON VARIABLE IMMUNODEFICIENCY; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; POLIOMYELITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA SEQUENCE; VACCINATION; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION;

HUMAN POLIOVIRUS 1; POLIOVIRUS; RNA VIRUSES;

EID: 0031688798     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.36.10.2893-2899.1998     Document Type: Article

References (38)

1. Aaronson, R. P., J. F. Young, and P. Palese. 1982. Oligonucleotide mapping: evaluation of its sensitivity by computer simulation. Nucleic Acids Res. 10:237-246.
2. Alexander, J. P., Jr., H. E. Gary, Jr., and M. A. Pallansch. 1997. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 175(Suppl. 1):S176-S182.
3. Blondel, B., R. Crainic, O. Fichot, G. Dufraisse, A. Candrea, D. Diamond, M. Girard, and F. Horaud. 1986. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J. Virol. 57:81-90.
4. Centers for Disease Control and Prevention. 1997. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 46:1-25.
5. Centers for Disease Control and Prevention. 1997. Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis. Morbid. Mortal. Weekly Rep. 46:641-643.
6. Cochi, S. L., R. W. Sutter, O. M. Kew, M. A. Pallansch, and W. R. Dowdle. 1997. A decision tree for stopping polio immunization. Technical Consultation on Global Eradication of Poliomyelitis. EPI/POLIO/TECH.97/WP18. World Health Organization, Geneva, Switzerland.
7. De, L., J. Jorba, J. Boshell, R. Salas, and O. Kew. 1998. Calibration of a clock for VP1 nucleotide variation in poliovirus type 1 during circulation in humans, abstr. W36-3, p. 123. In Abstracts of the 17th Annual Meeting of the American Society for Virology. American Society for Virology, Milwaukee, Wis.
8. De, L., B. K. Nottay, C.-F. Yang, B. P. Holloway, M. Pallansch, and O. Kew. 1995. Identification of vaccine-related polioviruses by hybridization with specific RNA probes. J. Clin. Microbiol. 33:562-571.
9. Domingo, E., and J. J. Holland. 1997. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-178.
10. Dowdle, W. R., and M. E. Birmingham. 1997. The biologic principles of poliovirus eradication. J. Infect. Dis. 175(Suppl. 1 ):S286-S292.
11. Felsenstein, J. 1993. PHYLIP (phylogeny inference package), version 3.5c. Department of Genetics, University of Washington, Seattle.
12. Fricks, C. E., J. P. Icenogle, and J. M. Hogle. 1985. Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles. J. Virol. 54:856-859.
13. Hatch, M. Unpublished data.
14. Hogle, J. M., M. Chow, and D. J. Filman. 1985. The three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229:1358-1365.
15. Hull, H. F., M. E. Birmingham, B. Melgaard, and J. W. Lee. 1997. Progress towards global polio eradication. J. Infect. Dis. 175(Suppl. 1):S4-S9.
16. Jones, D. T., W. R. Taylor, and J. M. Thornton. 1992. The rapid generation of mutation data matrices from protein sequences. Comput. Appl. Biosci. 8:275-282.
17. Kew, O. M., M. N. Mulders, G. Y. Lipskaya, E. E. da Silva, and M. A. Pallansch. 1995. Molecular epidemiology of polioviruses. Semin. Virol. 6:401-414.
18. Kew, O. M., and B. K. Nottay. 1984. Molecular epidemiology of polioviruses. Rev. Infect. Dis. 6(Suppl. 2):S499-S504.
19. Kilpatrick, D. R., B. Nottay, C.-F. Yang, S.-J. Yang, E. da Silva, S. Peñaranda, M. Pallansch, and O. Kew. 1998. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J. Clin. Microbiol. 36:352-357.
20. Kilpatrick, D. R., B. Nottay, C-F. Yang, S.-J. Yang, M. N. Mulders, B. P. Holloway, M. A. Pallansch, and O. M. Kew. 1996. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J. Clin. Microbiol. 34:2990-2996.
21. Kimura, M. 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16:111-120.
22. Lederman, H. M., and J. A. Winkelstein. 1985. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine 64:145-156.
23. Más Lago, P., C. Louzará, J. Beltrán, M. Jacobo, and R. Palomera. 1975. Circulación de poliovirus en la población infantil de Cuba. Bol. Oficina Sanit. Panam. 87:443-449.
24. McKinney, R. E., Jr., S. L. Katz, and C. M. Wilfert. 1987. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev. Infect. Dis. 9:334-356.
25. Minor, P. D. 1990. Antigenic structure of picornaviruses. Curr. Top. Microbiol. Immunol. 161:121-154.
26. Minor, P. D., M. Ferguson, A. Phillips, D. I. Magrath, A. Huovilainen, and T. Hovi. 1987. Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus. J. Gen. Virol. 68:1857-1865.
27. Nakano, J. H., H. M. Gelfand, and J. T. Cole. 1963. The use of a modified Wecker technique for the serodifferentiation of type 1 polioviruses related and unrelated to Sabin's vaccine strain. II. Antigenic segregation of isolates from specimens collected in field studies. Am. J. Hyg. 78:214-226.
28. Nomoto, A., T. Omata, H. Toyoda, S. Kuge, H. Horie, Y. Kataoka, Y. Genba, Y. Nakano, and N. Imura. 1982. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc. Natl. Acad. Sci. USA 79:5793-5797.
29. Nottay, B. K., O. M. Kew, M. H. Hatch, J. T. Heyward, and J. F. Obijeski. 1981. Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans. Virology 108:405-423 .
30. Rico-Hesse, R., M. A. Pallansch, B. K. Nottay, and O. M. Kew. 1987. Geographic distribution of wild poliovirus type 1 genotypes. Virology 160:311-322.
31. Rosen, F. S., M. D. Cooper, and R. J. P. Wedgwood. 1995. The primary immunodeficiencies. N. Engl. J. Med. 333:431-440.
32. Savilahti, E., T. Klemola, B. Carlsson, L. Mellander, M. Stenvik, and T. Hovi. 1988. Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polioviruses is prolonged. J. Clin. Immunol. 8:89-94.
33. Sutter, R. W., and R. Prevots. 1994. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect. Med. 11:426-438.
34. van Wezel, A. L., and A. G. Hazendonk. 1979. Intratypic serodifferentiation of poliomyelitis virus by strain-specific antisera. Intervirology 11:2-8.
35. World Health Organization. 1997. Manual for the virologic investigation of poliomyelitis. WHO/EPI/GEN/97.1. World Health Organization, Geneva, Switzerland.
36. Yang, C.-F., L. De, B. P. Holloway, M. A. Pallansch, and O. M. Kew. 1991. Detection and identification of vaccine-related polioviruses by the polymerase chain reaction. Virus Res. 20:159-179.
37. Yang, C.-F., and S.-J. Yang. Unpublished data.
38. Yoneyama, T., A. Hagiwara, M. Hara, and H. Shimojo. 1982. Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients. Infect. Immun. 37:46-53.